Amprologix presents at AMR conference in Basel
28 February 2025Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that…
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in…
Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections.…
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is…
October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE. For […]
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]
